Transformation of low grade glioma and correlation with outcome: An NCCTG database analysis

K. A. Jaeckle, P. A. Decker, K. V. Ballman, P. J. Flynn, Caterina Giannini, B. W. Scheithauer, Robert Brian Jenkins, Jan Craig Buckner

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Glioblastomas (GBM) may originate de novo (primary), or following transformation from a lower grade glioma (secondary), and it has been postulated that these tumors may have different biological behaviors. We performed a correlative analysis involving 204 patients with glioma treated prospectively on NCCTG clinical trials. Central pathology review of tumor tissues taken at the time of initial diagnosis and at recurrence were performed in all patients. Tumors progressed from low (WHO grade 2) to high (grade 3-4) at recurrence in 45% low grade oligodendroglioma patients, in 70% with low grade oligoastrocytoma, and 74% with low grade astrocytoma (P = 0.031). Median overall survival (OS) from initial diagnosis varied by histology: oligodendroglioma, 8.8 years; (95% CI 5.7-10.2); oligoastrocytoma, 4.4 years (95% CI 3.5-5.6); astrocytoma grade 2 3.1 years (astrocytoma grade 2-4, 2.1 years) (95% CI 1.7-2.5, P < 0.001). Mean time to recurrence (TTR) also varied between patients with de novo GBM, those secondary GBM, and those that remained non-GBM at recurrence (1.1 ± 1.1 vs. 2.9 ± 1.8 vs. 4.0 ± 2.9 years, respectively, P < 0.001). Median OS from time of recurrence also varied between these three categories (0.7 years, 95% CI: 0.5-1.1 vs. 0.6 years, CI: 0.5-1.0 vs. 1.4 years, 95% CI: 1.1-2.0, respectively) (P < 0.001). At time of relapse, transformation to higher grade is frequent in low grade pure and mixed astrocytomas, but is observed in less than half of those with low grade oligodendroglioma. From time of recurrence, OS was not significantly different for those with primary versus secondary GBM, and it may thus be reasonable include patients with secondary GBM in clinical therapeutic trials for recurrent disease.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalJournal of Neuro-Oncology
Volume104
Issue number1
DOIs
StatePublished - Aug 2011

Fingerprint

Glioma
Glioblastoma
Databases
Recurrence
Astrocytoma
Oligodendroglioma
Survival
Clinical Trials
Neoplasms
Histology
Pathology

Keywords

  • De-differentiation
  • Glioblastoma
  • Low grade glioma
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Transformation of low grade glioma and correlation with outcome : An NCCTG database analysis. / Jaeckle, K. A.; Decker, P. A.; Ballman, K. V.; Flynn, P. J.; Giannini, Caterina; Scheithauer, B. W.; Jenkins, Robert Brian; Buckner, Jan Craig.

In: Journal of Neuro-Oncology, Vol. 104, No. 1, 08.2011, p. 253-259.

Research output: Contribution to journalArticle

Jaeckle, K. A. ; Decker, P. A. ; Ballman, K. V. ; Flynn, P. J. ; Giannini, Caterina ; Scheithauer, B. W. ; Jenkins, Robert Brian ; Buckner, Jan Craig. / Transformation of low grade glioma and correlation with outcome : An NCCTG database analysis. In: Journal of Neuro-Oncology. 2011 ; Vol. 104, No. 1. pp. 253-259.
@article{ce84acf3209049949b12133ecd3e0588,
title = "Transformation of low grade glioma and correlation with outcome: An NCCTG database analysis",
abstract = "Glioblastomas (GBM) may originate de novo (primary), or following transformation from a lower grade glioma (secondary), and it has been postulated that these tumors may have different biological behaviors. We performed a correlative analysis involving 204 patients with glioma treated prospectively on NCCTG clinical trials. Central pathology review of tumor tissues taken at the time of initial diagnosis and at recurrence were performed in all patients. Tumors progressed from low (WHO grade 2) to high (grade 3-4) at recurrence in 45{\%} low grade oligodendroglioma patients, in 70{\%} with low grade oligoastrocytoma, and 74{\%} with low grade astrocytoma (P = 0.031). Median overall survival (OS) from initial diagnosis varied by histology: oligodendroglioma, 8.8 years; (95{\%} CI 5.7-10.2); oligoastrocytoma, 4.4 years (95{\%} CI 3.5-5.6); astrocytoma grade 2 3.1 years (astrocytoma grade 2-4, 2.1 years) (95{\%} CI 1.7-2.5, P < 0.001). Mean time to recurrence (TTR) also varied between patients with de novo GBM, those secondary GBM, and those that remained non-GBM at recurrence (1.1 ± 1.1 vs. 2.9 ± 1.8 vs. 4.0 ± 2.9 years, respectively, P < 0.001). Median OS from time of recurrence also varied between these three categories (0.7 years, 95{\%} CI: 0.5-1.1 vs. 0.6 years, CI: 0.5-1.0 vs. 1.4 years, 95{\%} CI: 1.1-2.0, respectively) (P < 0.001). At time of relapse, transformation to higher grade is frequent in low grade pure and mixed astrocytomas, but is observed in less than half of those with low grade oligodendroglioma. From time of recurrence, OS was not significantly different for those with primary versus secondary GBM, and it may thus be reasonable include patients with secondary GBM in clinical therapeutic trials for recurrent disease.",
keywords = "De-differentiation, Glioblastoma, Low grade glioma, Survival",
author = "Jaeckle, {K. A.} and Decker, {P. A.} and Ballman, {K. V.} and Flynn, {P. J.} and Caterina Giannini and Scheithauer, {B. W.} and Jenkins, {Robert Brian} and Buckner, {Jan Craig}",
year = "2011",
month = "8",
doi = "10.1007/s11060-010-0476-2",
language = "English (US)",
volume = "104",
pages = "253--259",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Transformation of low grade glioma and correlation with outcome

T2 - An NCCTG database analysis

AU - Jaeckle, K. A.

AU - Decker, P. A.

AU - Ballman, K. V.

AU - Flynn, P. J.

AU - Giannini, Caterina

AU - Scheithauer, B. W.

AU - Jenkins, Robert Brian

AU - Buckner, Jan Craig

PY - 2011/8

Y1 - 2011/8

N2 - Glioblastomas (GBM) may originate de novo (primary), or following transformation from a lower grade glioma (secondary), and it has been postulated that these tumors may have different biological behaviors. We performed a correlative analysis involving 204 patients with glioma treated prospectively on NCCTG clinical trials. Central pathology review of tumor tissues taken at the time of initial diagnosis and at recurrence were performed in all patients. Tumors progressed from low (WHO grade 2) to high (grade 3-4) at recurrence in 45% low grade oligodendroglioma patients, in 70% with low grade oligoastrocytoma, and 74% with low grade astrocytoma (P = 0.031). Median overall survival (OS) from initial diagnosis varied by histology: oligodendroglioma, 8.8 years; (95% CI 5.7-10.2); oligoastrocytoma, 4.4 years (95% CI 3.5-5.6); astrocytoma grade 2 3.1 years (astrocytoma grade 2-4, 2.1 years) (95% CI 1.7-2.5, P < 0.001). Mean time to recurrence (TTR) also varied between patients with de novo GBM, those secondary GBM, and those that remained non-GBM at recurrence (1.1 ± 1.1 vs. 2.9 ± 1.8 vs. 4.0 ± 2.9 years, respectively, P < 0.001). Median OS from time of recurrence also varied between these three categories (0.7 years, 95% CI: 0.5-1.1 vs. 0.6 years, CI: 0.5-1.0 vs. 1.4 years, 95% CI: 1.1-2.0, respectively) (P < 0.001). At time of relapse, transformation to higher grade is frequent in low grade pure and mixed astrocytomas, but is observed in less than half of those with low grade oligodendroglioma. From time of recurrence, OS was not significantly different for those with primary versus secondary GBM, and it may thus be reasonable include patients with secondary GBM in clinical therapeutic trials for recurrent disease.

AB - Glioblastomas (GBM) may originate de novo (primary), or following transformation from a lower grade glioma (secondary), and it has been postulated that these tumors may have different biological behaviors. We performed a correlative analysis involving 204 patients with glioma treated prospectively on NCCTG clinical trials. Central pathology review of tumor tissues taken at the time of initial diagnosis and at recurrence were performed in all patients. Tumors progressed from low (WHO grade 2) to high (grade 3-4) at recurrence in 45% low grade oligodendroglioma patients, in 70% with low grade oligoastrocytoma, and 74% with low grade astrocytoma (P = 0.031). Median overall survival (OS) from initial diagnosis varied by histology: oligodendroglioma, 8.8 years; (95% CI 5.7-10.2); oligoastrocytoma, 4.4 years (95% CI 3.5-5.6); astrocytoma grade 2 3.1 years (astrocytoma grade 2-4, 2.1 years) (95% CI 1.7-2.5, P < 0.001). Mean time to recurrence (TTR) also varied between patients with de novo GBM, those secondary GBM, and those that remained non-GBM at recurrence (1.1 ± 1.1 vs. 2.9 ± 1.8 vs. 4.0 ± 2.9 years, respectively, P < 0.001). Median OS from time of recurrence also varied between these three categories (0.7 years, 95% CI: 0.5-1.1 vs. 0.6 years, CI: 0.5-1.0 vs. 1.4 years, 95% CI: 1.1-2.0, respectively) (P < 0.001). At time of relapse, transformation to higher grade is frequent in low grade pure and mixed astrocytomas, but is observed in less than half of those with low grade oligodendroglioma. From time of recurrence, OS was not significantly different for those with primary versus secondary GBM, and it may thus be reasonable include patients with secondary GBM in clinical therapeutic trials for recurrent disease.

KW - De-differentiation

KW - Glioblastoma

KW - Low grade glioma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=80052752036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052752036&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0476-2

DO - 10.1007/s11060-010-0476-2

M3 - Article

C2 - 21153680

AN - SCOPUS:80052752036

VL - 104

SP - 253

EP - 259

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -